
AAPG Stock Forecast & Price Target
AAPG Analyst Ratings
Bulls say
Ascentage Pharma Group is positioned for success, based on its strong financial standing, partnerships, and potential revenue growth from its promising drugs in pipeline, including Olverembatinib and Lisaftoclax, which have shown positive results in clinical trials for treating blood cancers and solid tumors. Challenges in the form of slower adoption and delays in drug launches may arise, but the company's diversified pipeline and promising partnerships, such as with Takeda, make it a solid candidate for potential financial gains and further market success in both the United States and China.
Bears say
Ascentage Pharma Group is a clinical-stage biotechnology company with a focus on developing therapies for cancers and other diseases. Despite having promising drug candidates in their pipeline, the company faces competition from established players in the market, limiting potential growth. Additionally, enrollment or regulatory delays for their drug candidate lisaftoclax may push back launch timelines. While the company is already seeing success in China, scaling their commercial efforts and securing partnerships with more favorable economics will be key for sustained long-term growth.
This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.
AAPG Analyst Forecast & Price Prediction
Start investing in AAPG
Order type
Buy in
Order amount
Est. shares
0 shares